A recent report reveals a surprising trend: chocolate sales are increasing more rapidly among users of weight-loss medications such as Ozempic and Wegovy. This development contradicts earlier predictions that these drugs would diminish consumer interest in sweets. Swiss chocolatier Lindt & Sprüngli emphasized this shift, noting a growing preference for premium chocolate among individuals using GLP-1 medications like semaglutide and tirzepatide.
While users of these medications appear to be reducing their consumption of high-calorie foods like pasta and pizza, they are simultaneously seeking indulgent options, according to Adalbert Lechner, Chief Executive of Lindt. During a recent news conference, he stated, “They are upgrading to premium products. Less is more — small rewards with a moment of bliss rather than mindless munching.”
A company study indicates that approximately 15% of U.S. households are using GLP-1 medications. Notably, these households accounted for around 17.5% of chocolate sales in the analyzed dataset. Furthermore, Lindt reported a remarkable 17% increase in premium chocolate sales among GLP-1 users in 2025, compared to a more modest 6.5% growth among non-users.
Mixed Trends in Snack Spending
Despite Lindt’s optimistic outlook, a separate study conducted by Cornell University and Numerator presents a contrasting narrative. This research suggests that GLP-1 users have decreased their spending on calorie-dense snacks by approximately 10%, with significant reductions observed in categories such as sweets, baked goods, and cookies. Sylvia Hristakeva, an assistant professor and co-author of the Cornell study, stated, “The main pattern is a reduction in overall food purchases. Only a small number of categories show increases, and those are modest relative to the overall decline.”
Despite these findings, Lechner remains confident that the rise of weight-loss drugs will not threaten the confectionery market. Analysts had previously anticipated that the introduction of GLP-1 medications would negatively impact the food industry over the coming years. However, with the potential for oral versions of these medications to reach a broader demographic, including younger patients and men, the landscape may shift in unexpected ways.
As the chocolate market adapts to these changes, the broader implications for the food industry remain to be seen. Consumers worldwide are evidently searching for quality and moments of indulgence, even while navigating the challenges posed by weight-loss medications. Lindt’s focus on premium offerings may well exemplify the evolving consumer preferences in this complex market.